Trial Profile
A study evaluating effect of starting dose and dose intensity of sorafenib on survival in patients with hepatocellular carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 22 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology